Abstract:Introductionp53 plays important roles in regulating the metabolic reprogramming of cancer, such as aerobic glycolysis. Oroxylin A is a natural active flavonoid with strong anticancer effects both in vitro and in vivo.Methodswt-p53 (MCF-7 and HCT116 cells) cancer cells and p53-null H1299 cancer cells were used. The glucose uptake and lactate production were analyzed using Lactic Acid production Detection kit and the Amplex Red Glucose Assay Kit. Then, the protein levels and RNA levels of p53, mouse double minute 2 (MDM2), and p53-targeted glycolytic enzymes were quantified using Western blotting and quantitative polymerase chain reaction (PCR), respectively. Immunoprecipitation were performed to assess the binding between p53, MDM2, and sirtuin-3 (SIRT3), and the deacetylation of phosphatase and tensin homolog (PTEN). Reporter assays were performed to assess the transcriptional activity of PTEN. In vivo, effects of oroxylin A was investigated in nude mice xenograft tumor-inoculated MCF-7 or HCT116 cells.ResultsHere, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism in wt-p53 cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level. Oroxylin A did not directly affect the transcription of wt-p53, but suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells. In further studies, we found that oroxylin A induced a reduction in MDM2 transcription by promoting the lipid phosphatase activity of phosphatase and tensin homolog, which was upregulated via sirtuin3-mediated deacetylation. In vivo, oroxylin A inhibited the tumor growth of nude mice-inoculated MCF-7 or HCT116 cells. The expression of MDM2 protein in tumor tissue was downregulated by oroxylin A as well.ConclusionsThese results provide a p53-independent mechanism of MDM2 transcription and reveal the potential of oroxylin A on glycolytic regulation in both wt-p53 and mut-p53 cancer cells. The studies have important implications for the investigation on anticancer effects of oroxylin A, and provide the academic basis for the clinical trial of oroxylin A in cancer patients.

Involvement of P53 in Oroxylin A-induced Apoptosis in Cancer Cells.

Oroxylin A Modulates Mitochondrial Function and Apoptosis in Human Colon Cancer Cells by Inducing Mitochondrial Translocation of Wild-Type P53

Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

Oroxylin A Induced Apoptosis of Human Hepatocellular Carcinoma Cell Line HepG2 Was Involved in Its Antitumor Activity.

Oridonin Inhibits Bxpc-3 Cell Growth Through Cell Apoptosis

The Role of Nrf2 and Apoptotic Signaling Pathways in Oroxylin A-Mediated Responses in Hct-116 Colorectal Adenocarcinoma Cells and Xenograft Tumors

Triggering Apoptosis by Oroxylin A Through Caspase-8 Activation and P62/sqstm1 Proteolysis

Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells.

Oroxylin a promoted apoptotic extracellular vesicles transfer of glycolytic kinases to remodel immune microenvironment in hepatocellular carcinoma model

Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo.

Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest

Ucp2-Related Mitochondrial Pathway Participates in Oroxylin A-Induced Apoptosis in Human Colon Cancer Cells

Beclin 1-Mediated Autophagy in Hepatocellular Carcinoma Cells: Implication in Anticancer Efficiency of Oroxylin A Via Inhibition of Mtor Signaling.

Oroxylin A promotes cancer cell-to-macrophage communication and improves immunotherapy in hepatocellular carcinoma model

MAC Related Mitochondrial Pathway in Oroxylin A Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells

Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma.

Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells.

Oroxylin A Improves the Sensitivity of HT-29 Human Colon Cancer Cells to 5-FU Through Modulation of the COX-2 Signaling Pathway.

Oroxylin A Inhibits Glycolysis-Dependent Proliferation of Human Breast Cancer Via Promoting SIRT3-mediated SOD2 Transcription and HIF1α Destabilization

Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.

Oridonin Induces Apoptosis in SW1990 Pancreatic Cancer Cells Via P53- and Caspase-Dependent Induction of P38 MAPK